Summary
We have investigated the pharmacokinetics of the investigational semi-synthetic vinca alkaloid vinorelbine (navelbine, NVB). The analyses have been performed by using a sensitive and selective method based on ionexchange normal phase high-performance liquid chromatography with fluorescence detection combined with liquid-liquid extraction for sample clean-up. Pharmacokinetic studies were performed in male FVB mice receiving 12 mg/kg NVB through intravenous injection. The results have been compared to those obtained for vinblastine (VBL). The plasma pharmacokinetics of NVB can be described by a three compartment model. The elimination half-life is significantly longer and the plasma AUC values higher for NVB compared to VBL. This is reflected in tissues, where, 24 hr after drug administration, the concentration of NVB is 5 to 10-fold higher compared to VBL. Qualitatively, the tissue distribution and retention of the drugs is very similar. The drug concentrations in most tissues decline parallel with the circulating plasma levels, whereas prolonged retention is found in tissues of lymphatic and testicular origin. Deacetylation yielding deacetylnavelbine (DNVB) is the primary metabolic route for NVB. This cytotoxic metabolite accounts for a substantial part of the overall disposition of drug. Only 58% of the administered dose is excreted in the urine (17%) and faeces (41%) as NVB or DNVB. No other metabolites have been detected.
Similar content being viewed by others
References
Johnson IS, Armstrong JG, Gorman M, Burnett Jr JP: The vinca alkaloids: a new class of oncolytic agents. Cancer Res 23:1390–1427, 1963
Svoboda GH: Alkaloids from Vinca rosea Linn. IX. Extraction and characterization of leurosidine and leurocristine. Lloydia 24:173–178, 1961
Dyke RW, Nelson RL: Phase I anti-cancer agents Vindesine (desacetyl vinblastine amide sulfate). Cancer Treat Rev 4: 135–142, 1977
Cersosimo RJ, Bromer R, Licciardello JTW, Ki Hong W: Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid. Pharmacotherapy 3:259–274, 1983
Kreis W, Budman DR, Freeman J, Bergstrom RF, Nelson RL: Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. Cancer Chemother Pharmacol 26: 419–422, 1990
Pierré A, Kraus-Berthier L, Atassi G, Cros S, Poupon MF, Lavielle G, Berlion M, Bizzari JP: Preclinical antitumour activity of a new vinca alkaloid derivative, S 12363. Cancer Res 51:2312–2318, 1991
Ten Bokkel Huinink WW, Belpomme D, Franklin H, Fumoleau R, Verweij J: Phase II screening program of vintriptol in breast cancer, melanoma, colorectal cancer and lung cancer. Ann Oncol 3 (suppl 1): 126, 1992
Canobbio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, Santi L: Phase II study of navelbine in advanced breast cancer. Semin Oncol 2 (Suppl 4):33–37, 1989
George MJ, Heron JH, Kerbrat P, Chauvergne J, Goupil A, Lebrun D, Guastalla JP, Namer M, Bugat R, Ayme Y, Toussaint C, Lhomme C: Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers. Semin Oncol 2 (Suppl 4):30–33, 1989
Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC: A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 14:115–119, 1991
Yamamoto M, Furuse K, Hasegawa K, Kurita Y, Ariyoshi Y, Fukoka M, Niitani H: A phase I study of navelbine (vinorelbine) combined with cisplatin in non-small cell lung cancer patients. Ann Oncol 3 (suppl 1): 124, 1992
Dieras V, Extra JM, Morvan F, Bellissant E, Espie M, Giachetti S, Badri N, Marty M: Phase II study of navelbine (NVB) and fluorouracil (FU) in metastatic breast cancer (MBC) patients using a group sequential design (GSD). Ann Oncol 3 (suppl 1):125, 1992
George P, Journey LJ, Goldstein MN: Effect of vincristine on the fine structure of HeLa cells during mitosis. J Natl Cancer Inst 35:355–361, 1965
Journey LJ, Burdman J, George P: Ultrastructural studies on tissue culture cells treated with vincristine (NSC-67574). Cancer Chemother Rep 52:509–517, 1968
Ferguson PJ, Phillips JR, Selner M, Cass CE: Differential activity of vincristine and vinblastine against cultured cells. Cancer Res 44:3307–3312, 1984
Mujagic H, Chen SS, Geist R, Ochipinti SJ, Conger BM, Smith CA, Schuette WH, Schakney SE: Effects of vincristine on cell survival, cell cycle progression and mitotic asynchroneously growing sarcoma 180 cells. Cancer Res 43:3591–3597, 1983
Hill BT, Whelan DH: Comparative effects of vincristine and vindesine on cell cycle kineticsin vitro. Cancer Treat Rev 7 (suppl):5–15, 1980
Van Tellingen O, Sips JHM, Beijnen JH, Bult A, Nooijen WJ: Pharmacology, Bioanalysis and Pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives. Anticancer Res 12:1699–1715, 1992
Van Tellingen O, Beijnen JH, Nooijen WJ, Bult A: Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high performance liquid chromatography. Cancer Chemother Pharmacol, in press.
Castle MC, Margileth DA, Oliverio VT: Distribution and excretion of [3H]vinblastine in rat and the dog. Cancer Res 36:3684–3689, 1976
Noble RL, Gout PW, Wijcik LL, Hebden HF, Beer CT: The distribution of [3H]vincristine in tumour and host tissues of Nb rats bearing a transplantable lymphoma which is highly sensitive to the alkaloid. Cancer Res 37:1455–1460, 1977
El Dareer SM, White VM, Chen FP, Mellett LB, Hill DL: Distribution and metabolism of vincristine in mice, rats, dogs and monkeys. Cancer Treat Rep 61:1269–1277, 1977
Rahmani R, Zhou XJ, Placidi M, Martin M, Cano JP:In vivo andin vitro pharmacokinetics and metabolism of vinca alkaloids in rat. I. Vindesine (4-deacetyl-vinblastine-3-car-boxyamide). Eur J Drug Metab Pharmacokinet 15:49–55, 1990
Zhou XJ, Martin M, Placidi M, Cano JP, Rahmani R:In vivo andin vitro pharmacokinetics and metabolism of vinca alkaloids in rat. II. Vinblastine and vincristine. Eur J Drug Metab Pharmacokinet 15:323–332, 1990
Krikorian A, Rahmani R, Bromet M, Boré P, Cano JP: Pharmacokinetics and metabolism of navelbine. Semin Oncol 2 (Suppl 4):21–25, 1989
Bhushana Rao KSP, Hannart JA, Trouet A: Vinblastine-C4 alkyl maleoyl and amino acid maleoyl derivatives: I. Chemistry and physicochemical data. Anticancer Res 9: 619–624, 1989
Van Tellingen O, Kuijpers A, Beijnen JH, Baselier MRP, Burghouts JTM, Nooijen WJ: Bio-analysis of vinorelbine by high performance liquid chromatography with fluorescence detection. J Chromatogr 573:329–332, 1992
Van Tellingen O, Beijnen JH, Nooijen WJ: Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature. J Pharm Biomed Anal 9:1077–1082, 1991
Mathé G, Reizenstein P: Phase I pharmacologic study of a new vinca alkaloid: navelbine. Cancer Lett 27:285–293, 1985
Maral R, Bourut C, Chenu E, Mathé G: Experimental antitumour activity of 5′-nor-anhydrovinblastine navelbine. Cancer Lett 22:49–54, 1984
Lucas S, Donehower R, Rowensky E, Trump D, Weiner E, Wargin W, Hohneker J: Absolute bioavailability (ABA) and pharmacokinetics of weekly navelbine (NVB) liquid filled soft gelatin capsules at full therapeutic doses in patients (pts) with solid tumours. Ann Oncol 3 (suppl 1):125, 1992
Rahmani R, Martin M, Barbet J, Cano JP: Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5′-noranhydrovinblastine (navelbine). Cancer Res 44: 5609–5613, 1984
Rahmani R, Guéritte F, Martin M, Just S, Cano JP, Barbet J: Comparative pharmacokinetics of antitumour vinca alkaloids: intravenous bolus injection of navelbine and related alkaloids in cancer patients and rats. Cancer Chemother Pharmacol 16:223–228, 1986
Jehl F, Quoix E, Leveque D, Pauli G, Breillout F, Krikorian A, Monteil H: Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 51:2073–2076, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Tellingen, O., Kuijpers, A.V., Beijnen, J.H. et al. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. Invest New Drugs 11, 141–150 (1993). https://doi.org/10.1007/BF00874148
Issue Date:
DOI: https://doi.org/10.1007/BF00874148